MIAMI - TelAve -- Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain.

Aiming to be the First FDA-Approved Medication to Treat Suicidal Depression

Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC).

Actions Taken to Request the Removal of Benzethonium Chloride from Ketamine Products in Favor of the Company's Safer and Superior Options.

Agreement to Acquire Interest in Cohen and Associates, LLC for Network of Interventional Psychiatry Clinics.

Applied for New Commissioner's National Priority Vouchers (CNPV) for NRX-100 With Anticipated Decisions on Drug Approval by Year-End.

Application Under CNPV Program is Accretive to Already-Filed Abbreviated New Drug Application with Proprietary Formulation Under Priority Review Request.

Abbreviated New Drug Application Filed for Preservative-Free IV Ketamine.

Ketamine Market Estimated at $750 Million and Projected to Reach $3.35 Billion Globally in 2034.

$7.8 Million Debt Financing to Fuel NRXP HOPE Clinic Acquisitions with
Universal Capital, LLC.

Added to Previously Announced Term Sheet with a Strategic Investor, NRXP HOPE Funding of $10.3 Million is Planned in Near Term.

New Drug Application for Treatment of Suicidal Depression; Planned NDA for Accelerated Approval for Bipolar Depression in People at Risk of Akathisia.

Accepted Non-Binding Potential Terms to License and Distribute NRX-100 Drug Providing Over $300 Million in Milestones Plus Tiered Double-Digit Royalties.

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain

NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

More on TelAve News

• Bookmakers Review: Shohei Ohtani Leads 2025 TIME Athlete of the Year Betting Market
• OddsTrader Releases 2025-26 NFL Passing Leader Odds — Can Anyone Top Joe Burrow?
• Genpak Increases Foodservice Packaging Efficiency for Emerging Restaurants
• Where You Play Matters: MrBet Decodes Europe's Complex Gambling Tax Rules in New Report
• $1 Million Equity Dividend Ignites Investor Frenzy as AI & Cybersecurity Titans IQSTEL (N A S D A Q: IQST) & Cycurion (N A S D A Q: CYCU) Join Forces

Intravenous ketamine is widely accepted as a standard of care for acute treatment of suicidal depression, in the absence of an FDA-labeled product; the only treatment currently approved by the FDA is electroconvulsive therapy (ECT).  According to the CDC, 3.8 million Americans make a plan for suicide each year.

Final Clearance to Proceed to Closing of Dura Medical Acquisition from Florida's Agency for Health Care Administration (AHCA)

On August 8^th NRXP announced it has received final clearance and approval from the Florida Agency for Health Care Administration (AHCA) to proceed closing of its Dura Medical LLC acquisition, in connection with its change of ownership applications, a key regulatory step for closing.  Dura is revenue generating and EBITDA positive.

Dura Medical was founded in 2018 to offer a gold-standard, precision approach to treating mental health and chronic pain on the west coast of Florida.  The clinics leverage the latest interventional psychiatry procedures, including Ketamine Infusion Therapy, Transcranial Magnetic Stimulation (TMS), Spravato® and Stellate Ganglion Blocks, augmented by traditional psychiatry and therapy to provide a full continuum of care for people with depression, suicidality, PTSD, anxiety, and related disorders.

Request to the Food and Drug Administration Seeking Removal of Benzethonium Chloride from Ketamine Products to Favor a Switch to Better Options

On August 4^th NRXP announced its actions with the US Food and Drug Administration (FDA), seeking the removal of Benzethonium Chloride from ketamine sold in the United States. Benzethonium Chloride (BZT) is a preservative that is not Generally Recognized as Safe (GRAS) by the FDA for parenteral products and not Generally Recognized as Safe and Effective (GRASE) for topical products.  The FDA no longer allows BZT to be used in hand cleansers and topical antiseptics and other products on the market today for safety concerns. The ketamine versions made by NRXP is BZT free and therefore presents a safer and superior option.

In June 2025 NRXP filed an Abbreviated New Drug Application with the FDA for a preservative-free preparation of ketamine, demonstrating support for 3 year room temperature stability and sterility. NRXP has similarly filed a patent on its preservative-free process, in light of prior art that suggested BZT was required for long term stability and sterility. NRXP has instituted US-based high volume manufacture, while it awaits generic approval. The Company is additionally seeking a labeled indication for the use of ketamine to treat suicidal depression through the recently-announced FDA Commissioner's National Priority Voucher Program.

Agreement to Acquire Interest in Cohen and Associates, LLC for HOPE's Network of Interventional Psychiatry Clinics

On June 26^th NRXP announced the signing of a binding Letter of Intent to purchase a 49% interest in Cohen and Associates, LLC.  Cohen is expected to serve as a foundational clinic for NRXP in the Sarasota-Bradenton region of western Florida.

More on TelAve News

• From Paris to Rome to Venice — The World's No.1 Superstar™ Claims Another City with Bad Boy's Wild Ride
• Digital Dawn Launches Revolutionary Bitcoin Copy Trading Platform With 30-40% Monthly Returns
• Letter Four Launches Design-Build Decoded™ Podcast: Demystifying Architecture and Construction with AI Hosts
• Magnificent 63-Acre Equestrian Estate in Maryland's Horse Country Lists for $5.75M
• Shaping the Future of Congresses and Conventions: Osvaldo Rivera's Double Win at LAWA 2025

Cohen is one of the premier Interventional Psychiatry clinics in the region.  The clinic offers a full range of treatments for suicidal depression, PTSD and other CNS disorders, including ketamine, Spravato, Transcranial Magnetic Stimulation ("TMS") as well as medication management.  NRXP stated that this acquisition should be immediately accretive to revenue and EBITDA.

Filing of Commissioner's National Priority Voucher Application for Intravenous Ketamine (NRX-100)

On June 23^rd NRXP announced filing for the newly-announced FDA Commissioner's National Priority Voucher program on behalf of NRX-100, its patent-pending, preservative-free formulation of ketamine for intravenous use.

On June 17, 2025, FDA Commissioner Marty Makary, MD, MPH announced a new approval pathway, the Commissioner's National Priority Voucher (CPNV)1, for approval of drugs to enhance the health interests of Americans. Previously, on May 25 he identified psychedelic drugs for treatment of suicidal depression and PTSD as a national priority.2 The new voucher may be redeemed by drug developers to participate in a Commissioner-led program that shortens its review time from approximately 10-12 months to 1-2 months following a sponsor's final drug application submission.

To qualify for the CNPV, sponsors must submit the chemistry, manufacturing, controls (CMC) portion of the application and the draft labeling at least 60 days before submitting the final application. NRXP has already submitted the CMC portion for NRX-100 and received FDA feedback.

Strategic Investor Relations Partnership with astr partners

$7.8 Million Debt Financing to Fuel NRXP HOPE Clinic Acquisitions

HOPE's three initial acquisitions represent best-in-class clinics that offer neuroplastic treatments including NRXP ketamine and transcranial magnetic stimulation (TMS) to treat patients with severe depression, PTSD, and related central nervous system conditions. Neuroplastic treatments represent a rapidly emerging class of interventions that cause the growth of new connections (synapses) between brain cells that have been shown in multiple clinical trials to relieve symptoms of depression and suicidality. The FDA has approved TMS devices for a number of indications and has approved a nasal form of ketamine for treatment resistant depression. HOPE's parent company, NRXP, is currently applying to the FDA for approval of intravenous preservative-free ketamine to treat suicidal depression.

For more information on $NRXP visit: https://www.nrxpharma.com/ and https://compasslivemedia.com/case-study/nrx-pharmaceuticals/

Media Contact
Company Name: NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)
Contact Person: Matthew Duffy, Chief Business Officer

Company Website: https://www.nrxpharma.com/
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Home Country: United States

DISCLAIMER: https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website